Business
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 before the market opens. The press release will be available on the newsroom section of the Company’s website at https://perspectivetherap
About this update from Perspective Therapeutics, Inc.
[{"type":"image","alt":"Perspective Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Perspective Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/a27565ee8edf0640bed1250d2c58f3a9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QSFbVndZiJCez3FgWA5yTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a27565ee8edf0640bed1250d2c58f3a9","width":300,"height":63}},"lazy":false},{"type":"text","content":"SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 before the market opens. The press release will be available on the newsroom section of the Company’s website at https://perspectivetherapeutics.com/newsroom/press-releases.","length":540,"tagName":"p"},{"type":"text","content":"About Perspective Therapeutics, Inc.Perspective Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.","length":695,"tagName":"p"},{"type":"text","content":"The Company’s melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations.","length":368,"tagName":"p"},{"type":"text","content":"For more information, please visit the Company’s w...